Severity in words ("I have better and worse days") is not enough, for you or for the clinic. The IBS-SSS is the best-validated, free, patient-facing instrument for measuring IBS severity in a single number between 0 and 500 — comparable over time, comparable with clinical trials.
What is the IBS-SSS?
The IBS-SSS (Irritable Bowel Syndrome Severity Scoring System) is a standardised questionnaire for assessing IBS severity. Developed in 1997 by Francis, Morris, and Whorwell at the University Hospital of South Manchester and published in Aliment Pharmacol Ther (Francis 1997). It is the most widely used patient-reported severity instrument in IBS trials worldwide and is recognised as a patient-reported outcome measure (PROM) by the German DGVS S3 guideline (Layer 2021).
The IBS-SSS measures five dimensions of the IBS experience and sums them into a single number between 0 and 500. Higher means more severe. The score enables two things simple symptom logging cannot: a comparison over time (your score before and after an intervention) and a comparison with clinical trials (the cut-offs are internationally established).
The five questions in detail
The IBS-SSS has five items. Each item can contribute up to 100 points; their sum is the total score:
- 1. How severe was your abdominal pain over the past 10 days? Visual analogue scale 0–100.
- 2. How many of the past 10 days were affected by abdominal pain? Days × 10 (0 days = 0 points, 10 days = 100 points).
- 3. How severe was your bloating / abdominal distension over the past 10 days? Visual analogue scale 0–100.
- 4. How satisfied are you with your bowel habits? 100 minus your satisfaction (0–100). "Very satisfied" (100) scores 0 points; "not at all" (0) scores 100 points.
- 5. How much does IBS affect your daily life? Visual analogue scale 0–100.
The design is deliberately patient-centred. No item asks for lab values or clinical parameters — every score is self-reported. That is the point: the IBS-SSS measures how IBS feels in your life, not how it looks on paper.
Score interpretation — what the numbers mean
The original Francis et al. paper (Francis 1997) established the cut-offs that remain standard in clinical trials:
- Below 75: remission. Barely any symptoms. Score in the range of non-affected people.
- 75–175: mild IBS. Symptoms present but rare or weak. Daily life mostly unaffected.
- 175–300: moderate IBS. Regular, noticeable symptoms. Daily life impaired. Most often the range where people seek professional help.
- Above 300: severe IBS. Intense, frequent symptoms with clear daily-life limitation. Recommend gastroenterology assessment and, if needed, multidisciplinary care.
A change of 50 points or more is considered clinically relevant in the literature (MCID — minimum clinically important difference). If you scored 220 before a FODMAP phase and 160 after 6 weeks, that improvement is clinically meaningful — not measurement noise. Knowing the threshold lets you read your own data more calmly.
Worked example: how to compute your score
Example calculation, Anna, 34, IBS-M diagnosis, 6 months of symptoms:
| Item | Anna's answer | Points |
|---|---|---|
| 1. Pain intensity (0–100) | 70 | 70 |
| 2. Pain days (out of 10) | 7 days | 70 |
| 3. Bloating intensity (0–100) | 50 | 50 |
| 4. Stool satisfaction (inverted) | 30 (= 70 points) | 70 |
| 5. Daily-life impairment (0–100) | 60 | 60 |
| Total | 320 → severe IBS |
After 6 weeks of FODMAP elimination + gut-directed hypnosis Anna measures again: pain intensity 40, pain days 3, bloating 30, satisfaction 60 (= 40 points), daily life 50 → total 220. The difference is 100 points — clearly above the MCID threshold of 50. The effect is clinically relevant, not measurement noise.
To compute and log your score interactively, see the app at darmkompass/app/ibs-sss — including trend curve and automatic MCID flagging.
How often should you measure the IBS-SSS?
The DGVS guideline recommends the IBS-SSS not daily but as a periodic tracking instrument. What works in practice:
- Baseline at the start of every new intervention (FODMAP, medication, psychotherapy, exercise) — without it, there is no reference point.
- Mid-point at 4–6 weeks to check the direction of travel.
- End-point at 10–12 weeks to assess the overall result.
Measuring daily is not useful — the score responds to 10-day windows, not single days. Too-frequent scoring shows only noise. The useful daily tool is symptom logging (Bristol, pain, bloating); from those the IBS-SSS can be computed automatically.
Reading the IBS-SSS over time
A single score tells little — the signal comes from repeated measurement. Three patterns are worth knowing:
- Consistent improvement over 3 measurements. Baseline 280, mid-point 220, end-point 170 → your intervention works and it pays off to continue Phase 3 (personalisation) structured.
- Plateau after initial improvement. 300 → 240 → 235. The intervention has a partial effect, but headroom remains. Typical signal: add more levers (stress, sleep, movement — see the triggers article).
- No movement or worsening. 220 → 230 → 260 despite 6 weeks of strict Phase 1. The hypothesis is wrong — stop the intervention, re-orient with a clinician.
Typical effect sizes of interventions (derived from Ford 2019 (Ford 2019) and Black 2022 (Black 2022), adapted to the IBS-SSS scale): FODMAP elimination typically −80 to −100 points, CBT −60 to −90, gut- directed hypnosis −80 to −120 (Moser 2013), antidepressants −50 to −70 on average. Adding several levers is not additive — expect overlap rather than summation.
Seasonal patterns and cycle phases can shift the score too. A small rise in the luteal phase is not a loss of treatment effect but cycle- driven. The more measurement points you have across months, the easier such regularities become to recognise.
What the IBS-SSS does NOT show
Three important limits:
- It does not replace a diagnosis. A high score in a person without a clinician-confirmed IBS diagnosis may equally well point to another cause (inflammatory bowel disease, coeliac, microbiological infection). The IBS-SSS is designed for patients with a confirmed IBS diagnosis — for differentials see our red-flag symptoms article.
- It does not distinguish subtypes. It measures severity, not whether you have IBS-D, IBS-C, or IBS-M. That requires the Bristol distribution over several weeks — see our Bristol article.
- It ignores adjacent dimensions. Sleep quality, stress load, mild depression are not captured. With a persistently high score, a parallel HADS (Hospital Anxiety and Depression Scale) or PHQ-9 is worthwhile — the overlap is discussed at length in Ford et al. (Ford 2020).
Despite these limits, the IBS-SSS is the best available short instrument for severity. Measuring it regularly hands you a number at your next appointment that a clinician can place immediately — and lets you evaluate interventions objectively instead of relying on a diffuse "feels better/worse" impression.